Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SSTR2 | P30874 | 2/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | FOLH1 | Q04609 | 3/20 | 0.42 |
| ▸ | TTR | P02766 | 2/20 | 0.37 |
| ▸ | KCNK3 | O14649 | 1/20 | 0.32 |
| ▸ | CTSD | P07339 | 6/20 | 0.31 |
| ▸ | CTSE | P14091 | 6/20 | 0.31 |
| ▸ | BACE1 | P56817 | 4/20 | 0.31 |
| ▸ | MMP9 | P14780 | 1/20 | 0.31 |
| ▸ | XIAP | P98170 | 1/20 | 0.31 |
| ▸ | MLX | Q9UH92 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16580104 | 1.00 | SSTR2 (0.46) | SSTR2CYP3A4FOLH1TTRKCNK3 | |
| SCHEMBL24047111 | 1.00 | SSTR2 (0.46) | SSTR2CYP3A4FOLH1TTRKCNK3 | |
| SCHEMBL9892963 | 1.00 | SSTR2 (0.46) | SSTR2CYP3A4FOLH1TTRKCNK3 | |
| SCHEMBL20800137 | 1.00 | SSTR2 (0.46) | SSTR2CYP3A4FOLH1TTRKCNK3 | |
| SCHEMBL25295471 | 1.00 | SSTR2 (0.46) | SSTR2CYP3A4FOLH1TTRKCNK3 | |
| SCHEMBL24036409 | 1.00 | SSTR2 (0.46) | SSTR2CYP3A4FOLH1TTRKCNK3 | |
| SCHEMBL23900253 | 1.00 | SSTR2 (0.46) | SSTR2CYP3A4FOLH1TTRKCNK3 | |
| SCHEMBL24092997 | 1.00 | SSTR2 (0.46) | SSTR2CYP3A4FOLH1TTRKCNK3 | |
| SCHEMBL24047110 | 1.00 | SSTR2 (0.46) | SSTR2CYP3A4FOLH1TTRKCNK3 | |
| SCHEMBL22661595 | 1.00 | SSTR2 (0.46) | SSTR2CYP3A4FOLH1TTRKCNK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 3994 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026101236-A1 | PEPTIDES SPECIFICALLY BINDING TO CCR8, AND USE THEREOF | 경희대학교 산학협력단 | 2026-05-15 | — | — | WO | claimed |
| EP-3766510-B1 | CONJUGATES AND PRODRUGS FOR USE IN THE TREATMENT OF CANCER AND INFLAMMATORY DISEASES | CENTRE NAT RECH SCIENT (FR) | 2026-05-13 | — | — | EP | claimed |
| EP-4731263-A1 | BIO-CONJUGATES FOR ONCOLOGY | RDP Pharma AG (CH) | 2026-04-29 | — | — | EP | claimed |
| US-12605457-B2 | Modified EGFR antibody with reduced affinity, drug conjugate, and use thereof | Bliss Biopharmaceutical (Hangzhou) Co., Ltd. (CN) | 2026-04-21 | — | — | US | claimed |
| EP-3624854-B1 | PROTEIN-DRUG CONJUGATES AND THEIR USE IN THE TREATMENT OF CANCERS | UNIV STRASBOURG (FR) | 2026-04-15 | — | — | EP | claimed |
| US-20260083866-A1 | COMPOSITIONS TARGETING ENDOTHELIAL CELLS AND USES THEREOF | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2026-03-26 | — | — | US | claimed |
| US-12570748-B2 | Matrix metalloprotease-cleavable and serine or cysteine protease-cleavable substrates and methods of use thereof | CYTOMX THERAPEUTICS, INC. (US) | 2026-03-10 | — | — | US | claimed |
| US-20260062698-A1 | HIGH DRUG-LOADING RATIO APTAMER-DRUG CONJUGATES AND ITS APPLICATION | HANGZHOU INST OF MEDICINE CHINESE ACADEMY OF SCIENCE (CN) | 2026-03-05 | — | — | US | claimed |
| WO-2026043312-A1 | ALBUMIN-BINDING PRODRUG, ALBUMIN-DRUG CONJUGATE, METHOD FOR PREPARING ALBUMIN-DRUG CONJUGATE, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING CANCER COMPRISING SAME | 주식회사 키텍바이오 | 2026-02-26 | — | — | WO | claimed |
| EP-4692122-A1 | HUMANIZED ANTIBODIES TARGETING EPHA10 | Korea University Research and Business Foundation (KR) | 2026-02-11 | — | — | EP | claimed |
| WO-2022056200-A1 | METHODS AND COMPOSITIONS FOR POTENTIATING ANTITUMORAL IMMUNE RESPONSES THROUGH TARGETING OF NTPDASE3 | Purinomia Biotech, Inc. (US) | 2022-03-17 | — | — | WO | claimed |
| US-20220072084-A1 | THERAPEUTIC NANOCONJUGATES AND USES THEREOF | UNIVERSITAT AUTONOMA DE BARCELONA (UAB) (ES) | 2022-03-10 | — | — | US | claimed |
| EP-3247393-B1 | MATRIX METALLOPROTEASE-CLEAVABLE AND SERINE PROTEASE CLEAVABLE SUBSTRATES AND METHODS OF USE THEREOF | CYTOMX THERAPEUTICS INC (US) | 2022-03-09 | — | — | EP | claimed |
| CN-114133425-A | Method for modifying protein cysteine site by propargyl sulfonium salt and application thereof | 北京大学深圳研究生院 | 2022-03-04 | — | — | CN | claimed |
| EP-3960767-A2 | SPECIFIC SITES FOR MODIFYING ANTIBODIES TO MAKE IMMUNOCONJUGATES | Novartis AG (CH) | 2022-03-02 | — | — | EP | claimed |
| CN-114127121-A | Methods and compositions for promoting and enhancing T cell-mediated immune responses by ADCC targeting of CD39 expressing cells | 北京恩瑞尼生物科技股份有限公司 | 2022-03-01 | — | — | CN | claimed |
| CN-108026170-B | anti-CD 71 antibodies, activatable anti-CD 71 antibodies, and methods of use thereof | 西托姆克斯治疗公司 | 2022-03-01 | — | — | CN | claimed |
| WO-2022035244-A1 | COLON CANCER DIAGNOSIS OR DETECTION COMPOSITION FOR PREDICTING RESPONSE TO DRUG, AND COMPOSITION FOR PREVENTING OR TREATING COLON CANCER | 한국과학기술연구원 | 2022-02-17 | — | — | WO | claimed |
| WO-2022032020-A1 | IMMUNOCONJUGATES TARGETING CD46 AND METHODS OF USE THEREOF | FORTIS THERAPEUTICS, INC. (US) | 2022-02-10 | — | — | WO | claimed |
| CN-108112254-B | anti-PDL 1 antibodies, activatable anti-PDL 1 antibodies, and methods of use thereof | 西托姆克斯治疗公司 | 2022-01-28 | — | — | CN | claimed |